Compounds for the degradation of mutant braf

A compound of Formula:

• or a pharmaceutically acceptable salt thereof;
• wherein:
• Cycle {circle around (D)} is a spiroheterocyclyl containing 1 or 2 nitrogen atoms and containing no other heteroatoms or piperidine-1,4-diyl, wherein cycle {circle around (D)} is optionally substituted with one or two substituents independently selected from the group consisting of halogen, alkyl, and alkoxy;
• Cycle {circle around (E)} is a spiroheterocyclyl containing 1 nitrogen atom and 1 oxygen atom and containing no other heteroatoms, wherein cycle {circle around (E)} is optionally substituted with one or two substituents independently selected from the group consisting of halogen, alkyl, and alkoxy;
• A1 is —NR2— or —CHR2′—;
• R1 is hydrogen or alkyl;
• R2 is selected from the group consisting of hydrogen, alkyl, and haloalkyl;
• or R1 and R2 together with the nitrogen atom to which they are attached, form heterocycloalkyl optionally substituted with one or two R3 substituent(s);
• R2′ is selected from the group consisting of hydrogen, alkyl, and haloalkyl;
• or R1 and R2′ together with the carbon atom to which they are attached, form cycloalkyl optionally substituted with one or two R3 substituent(s);
• each R3 is independently selected from the group consisting of hydrogen, halogen, alkyl, and alkoxy;
• R4 is selected from the group consisting of hydrogen, alkyl, cyano, and halogen;
• R5 is selected from the group consisting of hydrogen, alkyl, cyano, and halogen;
• A2 is selected from the group consisting of —O—, —NH—, and —(C═O)—;
• R6 is selected from the group consisting of hydrogen, halogen, hydroxy, amino, dialkylamino, alkoxy, alkyl, and alkoxyalkyl;
• R7 is hydrogen or alkyl;
• R8 is selected from the group consisting of hydrogen, alkyl, cyano, halogen, and alkoxy;
• R9 is selected from the group consisting of hydrogen, alkyl, cyano, halogen, and alkoxy;
• and
• A5 is CH or N.